Best Grants for Museums in Pennsylvania

Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence Approach

Alopecia Areata (AA) is a chronic, immune-mediated condition causing nonscarring hair loss that affects about 2% of the global population and can lead to substantial psychosocial burden if disease is severe and untreated. The treatment landscape has recently evolved with the approval of ritlecitinib, a systemic therapy for severe AA in adults and adolescents aged 12 years and older, based on efficacy demonstrated in the ALLEGRO phase 2b/3 program.

Despite this advance, important questions remain regarding the optimal timing of therapy initiation. Emerging post-hoc analyses from the ALLEGRO program indicate that patients with shorter disease duration and lower baseline severity achieve higher response rates, suggesting that earlier intervention with ritlecitinib may lead to improved outcomes.

Geographic Scope

United States 

Funding Range and Project Length

Individual projects requesting up to $100,000 USD will be considered.

Maximum project length is 24 months.

Hemophilia Fellowship

This competitive grant program seeks to support an institution-based fellowship that emphasizes shared decision making (SDM), patient education, and multidisciplinary team-based care. The intent is to strengthen the hemophilia care through equitable education, and patient-centered shared decision making in a rapidly evolving treatment landscape.

Geographic Scope

• United States 

Funding Range and Project Length

• Grant funding is available to support a one year fellowship up to $100.000 USD. 

Accelerating the Development of Combined CGM–Pump Devices

A combined continuous glucose monitor (CGM) and insulin pump device represents an innovative approach to simplifying diabetes management by integrating two essential technologies into a single device. This approach has the potential to improve quality of life for people with type 1 diabetes (T1D) by reducing the burden associated with wearing and managing multiple devices.

Despite this promise, the development of combined CGM–pump devices presents technical and commercialization challenges. These include the need for further advances in device compatibility and lifespan, system reliability, and scalable manufacturing, while maintaining affordability and broadaccessibility. In addition, a potential insulin dilution effect may require adjustment of the CGM algorithm.

Breakthrough T1D invites applications for research and development projects that address key technical, clinical, and translational challenges related to combined CGM–pump devices, with the goal of accelerating their development and improving outcomes for people living with T1D.

In response to this announcement, applications may request up to a total of $900,000 USD for up to three years. 

The 2026 Rare Cancers Research Program Resource and Community Development Award aims to enhance rare cancer research through improved resources and datasets. It addresses critical gaps in research resources, communication strategies, and data sharing infrastructures. Key features include engaging patient advocates throughout the research process and ensuring sustainability of community platforms. This funding opportunity emphasizes community building and the dissemination of findings to benefit scientific and patient communities alike.

The FY26 Joint Warfighter Medical Research Program's Military Medical Research and Development Award aims to fund the continuation of previous Department of War-funded research addressing high-priority medical needs for Service Members and Military Health System beneficiaries. It supports various projects, including late-stage preclinical studies and clinical research. Eligibility requires prior DOD funding, and a Clinical Research Option is available for studies involving human subjects or biological samples.

The FY26 Bone Marrow Failure Research Program's Resource Development Award aims to create a multiomic atlas from human bone marrow failure samples. This resource will be open-access, providing essential data for researchers and clinicians to enhance their understanding of bone marrow failure diseases. A comprehensive Data Resource Sharing Plan is required to ensure timely availability of the developed resource, fostering collaboration within the scientific community.

The FY26 Parkinson’s Research Program Investigator-Initiated Research Award supports innovative, multidisciplinary research projects aimed at advancing the understanding and treatment of Parkinson’s disease. The award encourages collaboration among multiple principal investigators, requiring preliminary data and allowing clinical trials to enhance research outcomes. This initiative is vital for fostering impactful discoveries within the four specified focus areas of the program, ultimately improving patient care and management.

The FY 2027 DoN HBCU/MI Program aims to enhance the research capabilities of Historically Black Colleges and Universities and Minority Institutions. This initiative promotes innovative solutions to naval science challenges while engaging students and faculty in STEM fields. Key objectives include strengthening research infrastructure and fostering collaborative efforts across institutions. White papers are due by September 18, 2026, and should clearly outline the proposed advancements in naval-relevant science and technology.

The FY26 Parkinson’s Research Program (PRP) Early Investigator Research Award supports early-career researchers in Parkinson’s disease (PD) research. It offers two funding levels: Level 1 for fellows requiring a Mentor and Level 2 for independent investigators. The PI must show potential in PD research, with Level 1 emphasizing mentorship and Level 2 needing preliminary data. Research must align with one of the four FY26 PRP Focus Areas, excluding clinical trials.

The Fair Housing Initiatives Program (FHIP), established by Congress in 1988, aims to fund organizations to combat discriminatory housing practices. The Education and Outreach Initiative (EOI) educates stakeholders about their rights under fair housing laws. Key components include the National Media Campaign, which promotes fair housing awareness nationally, and local programs that support community-based outreach. HUD oversees the process, ensuring compliance and monitoring of funded initiatives to enhance fair housing practices.

An award from the George and Viola Hoffman Fund may be made annually for student research toward a master’s thesis or doctoral dissertation on a geographical subject in Eastern Europe. Eastern Europe includes the countries of East Central and Southeast Europe from Poland south to Romania, Bulgaria, and the successor states of the former Yugoslavia. Topics may be historical or contemporary, systematic or regional, limited to a small area or comparative.

The F26AS00104 State ANS Management Plan 2026 aims to combat aquatic nuisance species through pre-proposals followed by full applications. Managed by the US Department of the Interior's Fish and Wildlife Service, this initiative requires a 25% cost-share and limits administrative costs to 5%. Applications are due by October 14, 2026, though the funding opportunity closes on December 16, 2026. The plan is crucial for maintaining biodiversity and supporting a coordinated national approach to invasive species management.

The Child Protection Compact Annual Program Statement invites proposals aimed at combating child trafficking through collaborative efforts between the United States and other countries. This initiative focuses on enhancing the capacity to prosecute traffickers, providing care for victims, and implementing preventive measures. Organizations interested in applying must align with the objectives of the CPC to ensure comprehensive support and effective intervention against all forms of child trafficking.

The TIP Office of the US Department of State invites applications for projects aimed at combating human trafficking, adhering to the Trafficking Victims Protection Act. This initiative prioritizes prosecuting traffickers, protecting victims, and preventing trafficking through strategies outlined in the National Security Strategy, executive orders, and the annual Trafficking in Persons Report, while aligning with America First Foreign Policy priorities.

About Us

For more than 100 years, Duquesne Light Company has provided safe and reliable electric service to communities in southwestern Pennsylvania. Today, our core values of safety, integrity, dependability, equity and community enable us to serve more than 600,000 customers in two counties, including the city of Pittsburgh. We are committed to safely powering our customers’ lives while playing a leading role in our region’s clean energy transition. Our vision is to create a larger-than-light, clean energy future for all by delivering exceptional results today and boldly harnessing opportunities for tomorrow. In doing so, we can ensure a cleaner, healthier and more equitable community for generations to come.

Charitable Giving at Duquesne Light

Our Charitable Giving Grants Program is designed to help communities most affected by the rising cost of living—especially those burdened by high energy expenses. By prioritizing funding for nonprofit organizations helping individuals and families meet their basic needs and access high quality workforce development opportunities, we aim to reduce financial strain and promote long-term economic stability for residents across our service area.

Sponsorships

Duquesne Light Company is proud to support local events that strengthen and uplift our community. To be considered for sponsorship, all requests must be submitted through our online form. Please allow 4–6 weeks for our team to review your submission. Because of this timeline, we’re typically unable to sponsor events occurring within 30 days of the request. For questions regarding sponsorships, please email sponsorships@duqlight.com.

The DOW Combat Readiness – Medical Research Program's FY26 Translational Research Award supports innovative research aimed at improving trauma care outcomes. This program emphasizes hypothesis-driven studies that can transition promising technologies into practical solutions for enhancing casualty survivability. Applicants must provide preliminary data and utilize validated animal models, with a focus on projects that meet a minimum technology readiness level of 4, ensuring a mature translational research effort.

The National Institute of Allergy and Infectious Diseases (NIAID) is funding research to enhance drug susceptibility testing (DST) for mycobacteria. This initiative aims to improve testing for tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections, which are on the rise. Current methods are slow and ineffective against drug-resistant strains, making rapid DSTs essential for effective treatment and reducing transmission rates. Innovative approaches, including rapid genotypic and phenotypic methods, will be supported to address these challenges.

The Childhood Asthma in Urban Settings Clinical Research Network (CAUSE) aims to enhance asthma prevention and treatment in economically disadvantaged pediatric populations. Funded by the NIH, CAUSE supports multi-site clinical studies to identify innovative strategies and treatment targets for asthma. Utilizing systems biology, the network seeks to discover specific disease endotypes suitable for new therapeutic approaches, addressing the high burden of asthma in urban settings.

The BRAIN Initiative seeks to develop innovative tools and approaches for neuroscience research, focusing on cell-specific and circuit-specific processes within the central nervous system. This initiative encourages projects that enhance our understanding of brain architecture and function through novel technologies for characterizing neural components and advancing methods for recording and modulating neural activity. Applications are invited to address significant challenges and promote transformative breakthroughs in neuroscience.

The National Institute of Mental Health is inviting research applications for the AIDS Research Center program, which includes Developmental Centers and full Research Centers. This initiative aims to enhance interdisciplinary HIV/AIDS research through collaboration and innovative approaches across various scientific domains. The program emphasizes alignment with national strategies and encourages applications from teams skilled in fostering partnerships with diverse stakeholders. Although applications are currently not being solicited, this notice allows potential applicants time to prepare strong proposals.

The National Institute of Allergy and Infectious Diseases (NIAID) is advancing research on immune tolerance through its Collaborative Network. This program aims to clarify the mechanisms of immune tolerance and develop interventions for related diseases, including transplant rejection and autoimmune disorders. Key objectives include conducting clinical trials on tolerogenic strategies and refining immune assays. This initiative is supported by regulations under the Public Health Service Act, ensuring a structured approach to improving patient outcomes.

The Clinical Data, Safety and Statistical Centers (CDSSC) program, supported by the National Institute of Allergy and Infectious Diseases (NIAID), aims to enhance clinical research through comprehensive support. This includes statistical analysis, protocol development, and oversight of safety monitoring in studies related to asthma, autoimmune diseases, and transplantation. By coordinating these efforts, the program seeks to facilitate impactful research outcomes and improve public health outcomes through informed data-driven decisions.

The Translational Transplantation Tolerance Cooperative Study Group, supported by the National Institute of Allergy and Infectious Diseases, aims to advance transplant tolerance strategies that promote long-term graft survival without lifelong immunosuppression. This initiative focuses on developing, optimizing, and evaluating methods to induce immune tolerance in allogeneic transplants through collaborative efforts across multiple centers, utilizing translationally relevant models to ensure effective outcomes.

The PLTW Launch program, in collaboration with Burns and McDonnell, aims to enhance STEM education by expanding access to innovative educational modules in eligible schools. This initiative supports public and charter schools in targeted counties, focusing on increasing student engagement in STEM fields. Through grant funding, participating schools can introduce new PLTW Launch modules and provide essential training for teachers, fostering a richer learning environment to prepare students for future careers in science, technology, engineering, and mathematics.

The Pediatric Rheumatology Fellow Research Award, offered by the Rheumatology Research Foundation, recognizes exemplary scientific abstracts from pediatric rheumatology fellows at ACR Convergence. With a $1,500 award and an additional $1,000 for travel expenses, this initiative aims to promote innovative research and enhance educational opportunities for future rheumatologists. The program underscores the importance of developing a skilled workforce to improve access to specialized care for patients with rheumatic diseases.

The Marshall J. Schiff, MD, Memorial Fellow Research Award, established by the Rheumatology Research Foundation, aims to support exceptional scholarship in rheumatology. This award not only honors Dr. Schiff's legacy but also recognizes fellows presenting at ACR Convergence. Recipients receive a $1,500 award plus $1,000 for travel expenses, ensuring they can attend this crucial meeting, which showcases the latest advancements in rheumatic disease research and care.

The Fellowship Training Award for Workforce Expansion, offered by the Rheumatology Research Foundation, aims to improve access to rheumatology care by supporting the training of fellows at institutions facing funding constraints. This $50,000 per year award, available for up to three years, seeks to ensure a sufficient supply of rheumatology providers, particularly in underserved areas, thereby enhancing the quality of care for patients with rheumatic diseases.